Edition:
United States

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

2.70USD
21 Sep 2018
Change (% chg)

$-0.06 (-2.17%)
Prev Close
$2.76
Open
$2.76
Day's High
$2.79
Day's Low
$2.63
Volume
24,127
Avg. Vol
34,406
52-wk High
$20.40
52-wk Low
$2.03

Latest Key Developments (Source: Significant Developments)

Cellectar Biosciences Appoints Brian M. Posner As Chief Financial Officer
Wednesday, 4 Apr 2018 08:00am EDT 

April 4 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR BIOSCIENCES APPOINTS BRIAN M. POSNER AS CHIEF FINANCIAL OFFICER.POSNER JOINS CELLECTAR FROM ALLIQUA BIOMEDICAL, WHERE HE WAS CHIEF FINANCIAL OFFICER.  Full Article

Cellectar Reports 2017 Financial Results
Wednesday, 21 Mar 2018 04:10pm EDT 

March 21 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR REPORTS 2017 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.CELLECTAR BIOSCIENCES INC - ‍CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017 WERE ABOUT $10.0 MILLION​.CELLECTAR BIOSCIENCES INC - MANAGEMENT BELIEVES THAT CURRENT CASH AND CASH EQUIVALENTS ARE SUFFICIENT TO FUND BUDGETED OPERATIONS INTO Q1 OF 2019.  Full Article

Cellectar Biosciences On Jan 3, Notified Affected Employees Of Its Plan To Reduce Its Workforce By 6 Positions
Monday, 8 Jan 2018 08:57am EST 

Jan 8 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR BIOSCIENCES - ON JAN 3, NOTIFIED AFFECTED EMPLOYEES OF ITS PLAN TO REDUCE ITS WORKFORCE BY 6 POSITIONS -SEC FILING.CELLECTAR BIOSCIENCES-TO RECORD NON-CASH EXPENSES OF ABOUT $1.2 MILLION IN QUARTER ENDED DEC 31 & CASH COSTS OF ABOUT $0.2 MILLION IN 2018, RELATING TO SHUTDOWN.CELLECTAR BIOSCIENCES - IN JAN 2018, CO BEGAN IMPLEMENTING SHUTDOWN OF ITS MANUFACTURING OPERATIONS AT CO'S HEADQUARTERS IN MADISON, WISCONSIN.  Full Article

Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131
Wednesday, 6 Dec 2017 08:00am EST 

Dec 6 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131.CELLECTAR BIOSCIENCES - WILL INCREASE TARGETED PATIENT ENROLLMENT IN R/R MULTIPLE MYELOMA COHORT OF CO'S CURRENTLY ENROLLING CLR 131 PHASE 2 CLINICAL TRIAL.  Full Article

Cellectar Biosciences posts Q3 loss of $0.26 per share
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences reports third quarter 2017 financial and corporate performance.Q3 loss per share $0.26.Cash and cash equivalents as of September 30, 2017 were about $5.7 million​.  Full Article

Cellectar updates median overall survival from phase 1 trial in advanced multiple myeloma
Tuesday, 7 Nov 2017 08:30am EST 

Nov 7 (Reuters) - Cellectar Biosciences Inc ::Cellectar announces updated median overall survival of 26.2 months from cohort 1 of clr 131 phase 1 trial in advanced multiple myeloma.  Full Article

Cellectar Biosciences gets additional patent for CLR 131, CLR 125 in Japan
Tuesday, 17 Oct 2017 08:30am EDT 

Oct 17 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences receives additional Japanese patent for CLR 131 and CLR 125 for the treatment of various solid tumors.Japanese patent office granted it a patent covering both composition of matter and method of use for CLR 131 and CLR 125​.  Full Article

Cellectar Biosciences and Pierre Fabre extend collaboration
Tuesday, 10 Oct 2017 07:30am EDT 

Oct 10 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences and Pierre Fabre extend collaboration for development of new phospholipid drug conjugates.Cellectar Biosciences - ‍aim of extension is to further evaluate synergistic effects observed when Cellectar's phospholipid ethers are combined with Pierre Fabre's novel cytotoxic payloads​.Cellectar Biosciences - ‍program teams will continue to evaluate the new PDC compounds.  Full Article

Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics
Thursday, 21 Sep 2017 08:30am EDT 

Sept 21 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates.Cellectar Biosciences Inc - financial terms of collaboration have not been disclosed.Cellectar Biosciences - ‍under terms of collaboration, Onconova will provide Cellectar with several compounds, including some from family of molecules that contains briciclib​.Cellectar Biosciences Inc - both companies will have option to advance development of any of newly conjugated PDC molecules.  Full Article

Cellectar Biosciences Inc's Chad J. Kolean gave notice to co of his resignation as CFO
Friday, 18 Aug 2017 05:25pm EDT 

Aug 18 (Reuters) - Cellectar Biosciences Inc ::Cellectar Biosciences Inc - Chad J. Kolean gave notice to co of his resignation as vice president, CFO, treasurer of co, effective September 5, 2017.Cellectar Biosciences Inc - appointed John P. Hamill as interim Chief Financial Officer of company .  Full Article

BRIEF-Cellectar Granted Orphan Drug Designation For CLR 131

* CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA Source text for Eikon: Further company coverage: